---
title: Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy
nct_id: NCT05569382
overall_status: RECRUITING
phase: PHASE4
sponsor: Morten Steen Kvistholm Jensen
study_type: INTERVENTIONAL
primary_condition: Non-obstructive Hypertrophic Cardiomyopathy
countries: Denmark
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05569382.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05569382"
ct_last_update_post_date: 2025-03-20
last_seen_at: "2026-05-12T06:11:06.415Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy

**NCT ID:** [NCT05569382](https://clinicaltrials.gov/study/NCT05569382)

## Key Facts

- **Status:** RECRUITING
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 100
- **Lead Sponsor:** Morten Steen Kvistholm Jensen
- **Collaborators:** Viborg Regional Hospital, Zealand University Hospital, Odense University Hospital
- **Conditions:** Non-obstructive Hypertrophic Cardiomyopathy
- **Start Date:** 2022-08-10
- **Completion Date:** 2027-12-31
- **CT.gov Last Update:** 2025-03-20

## Brief Summary

Aim: to compare the treatment effects of Bisoprolol (beta 1 receptor specific beta blocker (BB)) and Verapamil (cardio-specific calcium channel blockers (CCB)) in patients with non-obstructive hypertrophic cardiomyopathy (HCM).

Background: Hypertrophic cardiomyopathy (HCM) is characterized by hypertrophy of the left ventricular wall and a hypercontracted state of the sarcomeres. This narrows the left ventricular cavity, but though the left ejection fraction is increased the stroke volume and the cardiac output cannot be fully compensated. The disease manifestations can be mild or develop into severe functional limitations and devastating complications at early age. Dyspnea, chest pain, palpitations and syncope are the most common symptoms, and patients are at risk of supraventricular and ventricular arrhythmias. Arrhythmias and sudden cardiac deaths may precede heart failure symptoms. Patients with symptomatic HCM are treated initially with beta blockers and calcium channel blockers. However, there is limited evidence supporting the effectiveness of this guideline-recommended treatment in HCM.

Methods: The study is a multicenter, double-blinded, randomized, placebo-controlled cross-over trial. Patients are randomized in to three 35-days treatment periods with Bisoprolol, Verapamil and Placebo. Each treatment period includes a 7-days up titration period, a 21-days target dose period and a 7-days down titration period. Between treatment periods 45 days treatment pause is allowed. End point will be evaluated at day 21 (- 4 days). Patients will be evaluated by cardiopulmonary exercise test, echocardiography, 7 day Holter-monitoring, biomarkers and the Kansas City Cardiomyopathy Questionnaire (KCCQ). A subgroup of patients will also be evaluated with cardiac magnetic resonance imaging.

Hypotheses: Three separate phases each with one primary effect parameters will be analyzed between treatment with Bisoprolol and Verapamil:

Phase 1: The maximal oxygen consumption (VO2 max) is different (ΔVO2 max ≥1 ml/kg/min) between treatments in non-obstructive HCM patients Phase 2: The left ventricular enddiastolic volume (LVvol) is different (ΔLVvol ≥3 ml) between treatments in non-obstructive HCM patients.

Phase 3: The incidence of non-sustained ventricular tachycardia (NSVT) is different (Hazard ratio ≥ 0.5) between treatments in non-obstructive HCM patients.

The trial will be performed and analyzed in three phases, and each phase may be unblinded and analyzed separately.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Age ≥ 18 years
* Maximal wall thickness ≥ 15 mm unrelated to hypertension, valve diseases or storage diseases. And one of the following:

  1. New York Heart Association - functional class (NYHA) ≥ II
  2. A history of NYHA class ≥ II before treatment with BB or CCB
  3. Pro-BNP\>300 ng/l/35\>nmol/l or BNP \>100ng/l/\>29nmol/l
  4. Non-sustained VT (\>120 min-1, ≥3 cycles) documented within the last 2 years of screening

Exclusion Criteria:

* Left ventricular ejection fraction \< 50%
* LVOT gradient \>30 mmHg at rest or during Valsalva maneuver after discontinuation of BB or CCB respectively
* History of LVOT gradient \>30 mmHg at rest, during exercise or during Valsalva maneuver.
* Permanent atrial fibrillation
* Permanent right ventricular pacing
* Previous intolerance for Bisoprolol (BB) or Verapamil (CCB)
* Known present obstructive coronary disease (previous percutaneous coronary intervention is accepted)
* eGFR \< 40 ml/min
* Fertile women (\<50 years) who are pregnant (Positive Plasma-HCG), breastfeeding or not using anticonception.
* Significant liver failure
* Severe valvular disease
* Bradycardia (40bpm)
* Hypotension (systolic \<100mmHg)
* Other significant comorbidity or risks associated with discontinuation of BB or CCB after individual judgement by the investigators.
* Unable to understand patient information intellectually or linguistically
* Unable to perform exercise test.
* Unable to speak and/or understand Danish.

Additional exclusion criteria for CMR sub study:

* Implantable cardioverter defibrillator (any kind)
* Pacemaker (any kind)
* Metal implants like to affect image quality
* Metal implants that poses a risk during CMR
* Inability to cope with being in the scanner.
```

## Arms

- **Verapamil** (ACTIVE_COMPARATOR) — Maximal tolerable dose (up to 360 mg per day)
- **Bisoprolol** (ACTIVE_COMPARATOR) — Maximal tolerable dose (up to 7,5 mg per day)
- **Placebo** (PLACEBO_COMPARATOR) — Matching placebo

## Interventions

- **Verapamil** (DRUG) — 1\. week: uptitration with 120 mg capsules per day, until maximum dosage of 360 mg´s/day.

2-4. week: steady state treatment with the maximum tolerated dose.

5\. week: downtitration
- **Bisoprolol** (DRUG) — 1\. week: uptitration with 2.5 mg capsules per day, until maximum dosage of 7.5 mg´s/day.

2-4. week: steady state treatment with the maximum tolerated dose.

5\. week: downtitration
- **Placebo** (DRUG) — 1\. week: uptitration with one capsules per day, until maximum dosage of three capsules/day.

2-4. week: steady state treatment with the maximum tolerated dose.

5\. week: downtitration

## Primary Outcomes

- **Maximal oxygen consumption (VO2 max)** _(time frame: Changes will be evaluated at day 21 in each treatment arm)_ — Changes in VO2 max estimated during cardiopulmonary exercise test
- **Left ventricular enddiastolic volume (LVvol)** _(time frame: Changes will be evaluated at day 21 in each treatment arm)_ — Changes in enddiastolic volume (LVvol) estimated during cardiac MRI
- **Incidence of non-sustained ventricular tachycardia (NSVT** _(time frame: Changes will be evaluated at day 21 +7 days in each treatment arm)_ — Changes in NSVT estimated during ECG monitoring

## Secondary Outcomes

- **Kansas City Cardiomyopathy Questionnaire (KCCQ) score** _(time frame: Changes will be evaluated at day 21 in each treatment arm)_
- **New York Heart Association (NYHA) functional classification** _(time frame: Changes will be evaluated at day 21 in each treatment arm)_
- **Canadian Cardiovascular Society (CCS) class** _(time frame: Changes will be evaluated at day 21 in each treatment arm)_
- **Pro-BNP/BNP** _(time frame: Changes will be evaluated at day 21 in each treatment arm)_
- **High sensitive Troponin I/Troponin T** _(time frame: Changes will be evaluated at day 21 in each treatment arm)_
- **Metabolic equivalent of task (METs)** _(time frame: Changes will be evaluated at day 21 in each treatment arm)_
- **Recovery time** _(time frame: Changes will be evaluated at day 21 in each treatment arm)_
- **VO2 max Anaerobic threshold** _(time frame: Changes will be evaluated at day 21 in each treatment arm)_
- **Percent predicted VO2 max** _(time frame: Changes will be evaluated at day 21 in each treatment arm)_
- **Ventilatory equivalent for carbon dioxide VE/VCO2** _(time frame: Changes will be evaluated at day 21 in each treatment arm)_
- **Echocardiographic left ventricular end-diastolic dimension** _(time frame: Changes will be evaluated at day 21 in each treatment arm)_
- **Echocardiographic global longitudinal strain (GLS) for LV function** _(time frame: Changes will be evaluated at day 21 in each treatment arm)_
- **Echocardiographic left ventricular outflow tract time velocity intergral (LVOT VTI) for LV function** _(time frame: Changes will be evaluated at day 21 in each treatment arm)_
- **Echocardiographic dimension of left atrial** _(time frame: Changes will be evaluated at day 21 in each treatment arm)_
- **Episodes of atrial fibrillation (AFIB) on Holter monitoring** _(time frame: Changes will be evaluated at day 21 +7 days in each treatment arm)_
- **Number of ventricular ectopic beats on Holter monitoring** _(time frame: Changes will be evaluated at day 21 +7 days in each treatment arm)_
- **Left ventricular systolic function on Cardiac MRI** _(time frame: Changes will be evaluated at day 21 in each treatment arm)_
- **Right ventricular dimensions on Cardiac MRI** _(time frame: Changes will be evaluated at day 21 in each treatment arm)_
- **Right ventricular systolic function on Cardiac MRI** _(time frame: Changes will be evaluated at day 21 in each treatment arm)_
- **Stroke volume (Aortic flow) on Cardiac MRI** _(time frame: Changes will be evaluated at day 21 in each treatment arm)_
- **Coronary sinus flow on Cardiac MRI** _(time frame: Changes will be evaluated at day 21 in each treatment arm)_
- **Dimension of inferior and superior caval vein on Cardiac MRI** _(time frame: Changes will be evaluated at day 21 in each treatment arm)_
- **Dimension of left atrium on cardiac MRI** _(time frame: Changes will be evaluated at day 21 in each treatment arm)_
- **Sex specific analyses of outcome measures** _(time frame: Changes will be evaluated at day 21 in each treatment arm)_

## Locations (4)

- Department of Cardiology, Aarhus University Hospital, Aarhus N, Denmark — _RECRUITING_
- Department of Cardiology, Odense University Hospital, Odense, Denmark — _RECRUITING_
- Department of Cardiology, Zealand University Hospital, Roskilde, Denmark — _NOT_YET_RECRUITING_
- Department of Cardiology, Regional Hospital Viborg, Viborg, Denmark — _NOT_YET_RECRUITING_

## Recent Field Changes (last 30 days)

- `locations.department of cardiology, regional hospital viborg|viborg||denmark` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `locations.department of cardiology, aarhus university hospital|aarhus n||denmark` — added _(2026-05-12)_
- `locations.department of cardiology, odense university hospital|odense||denmark` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.department of cardiology, zealand university hospital|roskilde||denmark` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05569382.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05569382*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*